Optimizing Tebra Prior Authorization for Dermatology Practices

Klivira automates **Tebra prior authorization for dermatology**, streamlining complex requests for biologics, specialty drugs, and Mohs surgery directly within your existing EHR workflow.

Independent dermatology practices leveraging Tebra (formerly Kareo and PatientPop) face significant administrative burdens managing prior authorizations. The high volume of specialty medications and procedures unique to dermatology often strains lean revenue cycle teams, impacting patient access and practice profitability. Klivira provides a targeted solution.

The Specific Prior Authorization Demands of Dermatology in Tebra

Dermatology practices, often serving small independent clinics using Tebra, navigate frequent prior authorization requirements for high-cost biologics and specific procedures. This includes medications like Dupixent, Cosentyx, Tremfya, and Skyrizi for conditions such as psoriasis and atopic dermatitis, alongside high-volume procedures like Mohs micrographic surgery.

Key PA-Triggering Categories in Dermatology

Biologics for psoriasis and psoriatic arthritis (e.g., adalimumab, secukinumab, guselkumab, risankizumab)
Biologics for atopic dermatitis (e.g., dupilumab, tralokinumab)
Hidradenitis suppurativa biologics (e.g., adalimumab, secukinumab)
Mohs micrographic surgery for non-melanoma skin cancers in sensitive areas
Advanced skin cancer treatments (e.g., immunotherapy for melanoma)
Phototherapy, particularly when prescribed for home administration

Seamless Klivira Integration with Tebra for Dermatology Workflows

Klivira integrates with Tebra's EHR via the Tebra API, embedding prior authorization automation directly into your clinical and administrative workflows. This allows dermatology practices to initiate, track, and manage PA requests from within the Tebra environment, minimizing context switching and manual data entry for orders related to biologics or procedures.

Addressing Common Dermatology Prior Authorization Denials Proactively

Klivira helps Tebra users proactively mitigate common denial reasons specific to dermatology. Our platform ensures robust documentation of step therapy compliance for psoriasis biologics, verifies Mohs Appropriate Use Criteria (AUC) match, and confirms disease severity scores (e.g., PASI, EASI, BSA), reducing the need for costly appeals and resubmissions. We also support the required TB and hepatitis screening documentation pre-biologic.

Optimizing Revenue Cycle for Tebra Dermatology Practices

For independent dermatology clinics using Tebra, efficient prior authorization directly impacts financial health. Klivira's automation reduces administrative overhead, accelerates approval times for high-value treatments, and improves clean submission rates. Our platform is designed to handle periodic re-authorization cycles for chronic biologic treatments and correctly route requests based on medical-vs-pharmacy benefit distinctions, enhancing overall revenue cycle performance.

Klivira's Intelligent Automation for Dermatology PA

Klivira's platform employs AAD-guideline-aware step-therapy logic for biologics and AUC validation for Mohs surgery. This intelligent automation ensures that prior authorization requests initiated from Tebra are accurately prepared according to payer-specific requirements and clinical guidelines, improving first-pass approval rates for critical dermatology treatments.

Frequently asked questions

How does Klivira handle step therapy requirements for biologics in Tebra?

Klivira's platform integrates with Tebra to capture necessary clinical documentation, such as prior topical or systemic therapy trials, and then applies AAD-guideline-aware step-therapy logic to ensure PA requests comply with payer requirements before submission, reducing denial rates.

Can Klivira help with Mohs surgery prior authorizations within Tebra?

Yes, Klivira validates Mohs surgery requests against Appropriate Use Criteria (AUC) and payer policies. Our integration with Tebra allows for the efficient collection of required documentation (site, tumor type, prior treatment) to support a clean PA submission for Mohs procedures.

Does Klivira support re-authorization for chronic dermatology treatments?

Absolutely. Klivira manages the workflow for periodic re-authorization cycles common for chronic biologic treatments in dermatology. Our system tracks re-authorization due dates and prompts staff within Tebra to initiate the process, ensuring continuous patient access to critical medications.

What clinical guidelines does Klivira use for dermatology PAs?

Klivira's automation leverages AAD Clinical Guidelines for conditions like psoriasis and atopic dermatitis, and NCCN guidelines for skin cancers. We incorporate these frameworks to ensure that documentation requirements and step therapy protocols align with established clinical best practices.

How does Klivira integrate with my existing Tebra EHR?

Klivira integrates directly with Tebra via its API. This allows for the seamless initiation and tracking of prior authorization requests from within your Tebra EHR, pulling relevant patient data and clinical notes to populate PA forms and reducing manual data entry.